ClinicalTrials.gg
Not yet recruitingNCT07154160Updated Nov 2, 2026

Closed-loop TMS for the Core Clinical Features of Methamphetamine Use Disorder

An interventional study of Closed-loop TMS and Conventional TMS in Methamphetamine Use Disorder, Substance Use Disorder and Cue-reactivity, sponsored by Shanghai Mental Health Center. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Shanghai Mental Health Center · Not applicable, Interventional, and Treatment

How we know

Updated Nov 2, 2026Start date movedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Substance-Related Disorders with a site in China — 7 open to participants now, 8 under way, none of them phase 3. Substance-Related Disorders · China.

Planned enrollment
13th of 16
21 · median 82
Started
2026
with 3 others
No phase
16 of 19
6 open now
Registered
16th of 19
by date
Lead sponsor
6 of 19
Shanghai Mental Health Center

Among the 19 studies in Substance-Related Disorders with a site in China, this one is the 13th largest by planned enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2026, is one of 16 with no phase, and was the 16th registered.

Substance-Related Disorders

2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

7 of the 19 studies in Substance-Related Disorders with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Substance-Related Disorders with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether closed-loop transcranial magnetic stimulation (TMS) targeting left-dorsolateral prefrontal cortex (l-DLPFC) can improve core clinical symptoms in individuals with methamphetamine use disorder (MUD), such as cue-reactivity and impaired inhibitory control.

The main questions it aims to answer are:

Can closed-loop TMS targeting l-DLPFC significantly reduce cue-reactivity, as measured by a Visual Analog Scale (VAS) and cue-reactivity task, compared to a conventional treatment protocol and random TMS ? Does closed-loop stimulation targeting l-DLPFC enhance cognitive control, assessed by performance on the Stop Signal Task (SST), more effectively than the other stimulation modes? Researchers will compare closed-loop, conventional, and random TMS conditions targeting l-DLPFC to determine whether closed-loop yields superior symptom improvement.

Participants will:

Be randomly assigned to one of the three stimulation groups (closed-loop, conventional and random) according to a pre-generated random number table, and receive the corresponding stimulation session targeting l-DLPFC.

Undergo cue-reactivity assessment using VAS and cue-reactivity task, and complete the SST before and after each stimulation session.

03

Conditions studied

  • Methamphetamine Use Disorder
  • Substance Use Disorder
  • Cue-reactivity
  • Craving
04

Who can participate

The criteria were revised on the registry on Nov 2, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years old or older, with at least 9 years of education (junior high school or above) or able to fully understand the task.
  • Meets Meets , Fifth Edition (DSM-5) for mild/severe amphetamine-type substance use disorder.
  • History of amphetamine-type substance use for no less than 1 year, with use at least once per week.

Exclusion criteria

Exclusion Criteria:

  • Presence of any organic disease, or diagnosis of any other psychiatric disorder according to (e.g., bipolar disorder, major depression disorder).
  • to TMS, as assessed by the Transcranial Magnetic Stimulation Adult Safety Screen (TASS).
  • Inability to complete assessments, treatment procedures, or follow-up due to cognitive or behavioral limitations.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    Closed-loop Group

    Participants in this arm will receive closed-loop TMS. Before stimulation: The researchers measure the participant's Resting Motor Threshold (RMT) and assess their craving using VAS before and after viewing a methamphetamine-related video. The participants complete SST. During the stimulation phase, participants will: First undergo a training phase, during which EEG is recorded while they perform a cue-reactivity task to identify neural signatures and calculate stimulation thresholds. Then perform the cue-reactivity task again, and real-time EEG features are used to trigger TMS in a closed-loop mode, targeting l-DLPFC. After the stimulation, participants will: The researchers again assess their craving using VAS before and after viewing the video. The participants again complete the SST. The researchers record adverse reactions and adverse events, and evaluate the blinding effect, through a Blinding Assessment Questionnaire.

    Device: Closed-loop TMS

  • Active comparator
    Conventional TMS Group

    Participants in this arm will receive conventional TMS. Before stimulation: The researchers measure the participant's RMT and assess their craving using VAS before and after viewing a methamphetamine-related video. The participants complete SST. During the stimulation phase, participants will: First undergo a training phase, during which EEG is recorded while they perform a cue-reactivity task to identify neural signatures and calculate stimulation thresholds. Then receive a TMS treatment delivered at a conventional iTBS protocol, targeting l-DLPFC, and perform the cue-reactivity task again afterwards. After the stimulation, participants will: The researchers again assess their craving using VAS before and after viewing a methamphetamine-related video. The participants again complete the SST. The researchers record adverse reactions and adverse events, and evaluate the blinding effect, through a Blinding Assessment Questionnaire.

    Device: Conventional TMS

  • Active comparator
    Random Group

    Participants in this arm will receive random TMS. Before stimulation: The researchers measure the participant's Resting Motor Threshold (RMT) and assess their craving using VAS before and after viewing a methamphetamine-related video. The participants complete SST. During the stimulation phase, participants will: First undergo a training phase, during which EEG is recorded while they perform a cue-reactivity task to identify neural signatures and calculate stimulation thresholds. Then perform the cue-reactivity task again, and TMS is triggered by a random sequence unrelated to real-time EEG features, targeting l-DLPFC. After the stimulation, participants will: The researchers again assess their craving using VAS before and after viewing a methamphetamine-related video. The participants again complete the SST. The researchers record adverse reactions and adverse events, and evaluate the blinding effect, through a Blinding Assessment Questionnaire.

    Device: Random TMS

Interventions

  • DeviceClosed-loop TMS

    Participants receive theta burst stimulation (TBS) targeting l-DLPFC, triggered by real-time EEG signals recorded during a cue-reactivity task. This closed-loop protocol aims to deliver stimulation precisely during neural states associated with cue-induced craving.

    Also known as: EEG-TMS, Closed-loop TBS, EEG triggered TMS

  • DeviceConventional TMS

    Participants receive TBS targeting l-DLPFC, delivered at a standard iTBS protocol (3-pulse 50-Hz bursts given at every 200 ms (i.e. at 5 Hz), 2s on and 8s off, with 1200 pulses in total), without EEG or task engagement.

  • DeviceRandom TMS

    Participants receive TBS targeting l-DLPFC, triggered by a random sequence unrelated to real-time EEG features.

06

What researchers measure

Primary outcomes

  1. Cue-Induced Neural Reactivity During Before and After Stimulation

    EEG signals will be recorded while participants perform a cue-reactivity task during both the training phase (no stimulation) and the stimulation phase (with TMS). The primary outcome will be changes in cue-induced neural reactivity, defined by EEG features in response to methamphetamine-related cues identified in previous studies, which are also implemented to trigger stimulation in this trial. Comparisons will be made across phases (pre- vs. during stimulation) and stimulation conditions (closed-loop, conventional, random).

    Time frame: During cue-reactivity task in training and stimulation phases of each session.

Secondary outcomes

  1. Change in Cue-Induced Craving Measured by Visual Analog Scale (VAS)

    Participants will rate their craving levels after viewing methamphetamine-related videos using a Visual Analog Scale (VAS), ranging from 0 (no craving) to 100 (maximum craving). Craving scores will be recorded immediately before and after each stimulation session under all three stimulation conditions.

    Time frame: Before and within 30 minutes after stimulation

  2. Change in Inhibitory Control Assessed by Stop Signal Task (SST)

    Participants will complete the Stop Signal Task (SST) before and after each stimulation session. Measures such as Stop Signal Reaction Time (SSRT) will be used to assess changes in inhibitory control performance across different stimulation conditions.

    Time frame: Before and within 30 minutes after stimulation

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2026, 0 months later.

Of 819 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 0 months is below that.

Counting every sponsor, half of 859 studies reached it within 34 months; a quarter within 17 and three quarters within 53.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Aug 2026 → Oct 2026 and primary completion Sep 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 4, 2025
StartEst.
Oct 2026was Aug 2026
Primary completionEst.
Oct 2026was Sep 2026
CompletionEst.
Dec 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2026→Oct 2026
Nov 2, 2026
Primary completion
Sep 2026→Oct 2026
Nov 2, 2026
Eligibility
2 inclusion criteria edited, 1 added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedAged 18 years old or older, ....with at least 9 years of education (junior high school or above) or able to fully understand the task.
  • AddedMeets Meets Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) for mild/severe amphetamine-type substance use disorder.
  • EditedMeets DSM-5 for mild/severe amphetamine-type substance use disorder. History of amphetamine-type substance use for no less than 1 year, with use at least once per week.
  • RemovedHas not received pharmacological treatment for substance use.
Nov 2, 2026
Interventions
Arm changed Sham Group→Random Group
Nov 2, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionCue-Induced Neural Reactivity During Before and After Stimulation: how it is measured was reworded
Nov 2, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionChange in Inhibitory Control Assessed by Stop Signal Task (SST): how it is measured was reworded
Nov 2, 2026
Title
Closed-loop TMS for the Core Clinical Features of the Methamphetamine Use Disorder
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Start date Aug 2026→Oct 2026
    Primary completion Sep 2026→Oct 2026
    Eligibility 2 inclusion criteria edited, 1 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedAged 18 years old or older, ....with at least 9 years of education (junior high school or above) or able to fully understand the task.
    • AddedMeets Meets Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) for mild/severe amphetamine-type substance use disorder.
    • EditedMeets DSM-5 for mild/severe amphetamine-type substance use disorder. History of amphetamine-type substance use for no less than 1 year, with use at least once per week.
    • RemovedHas not received pharmacological treatment for substance use.
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionCue-Induced Neural Reactivity During Before and After Stimulation: how it is measured was reworded
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionChange in Inhibitory Control Assessed by Stop Signal Task (SST): how it is measured was reworded
    Interventions Arm changed Sham Group→Random Group
    Title Closed-loop TMS for the Core Clinical Features of the Methamphetamine Use Disorder
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07154160
Responsible party
Sponsor
First posted
Sep 4, 2025
Start date
Oct 2026 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 2, 2026

Study contacts

Min Zhao, PhD
Contact
drminzhao@smhc.org.cn
+86 18017311005
Min Zhao, PhD
study chair · Shanghai Mental Health Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion